Q-omics provides the consensus-scored MYO7B profile across patient tissues and cancer cell-line models. MYO7B expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MYO7B is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, MYO7B RNA expression shows 13,789 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UVM, KICH, and ESCA as cancer lineages where MYO7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO7B survival associations across molecular data types. MYO7B RNA expression shows survival associations in the most cancer types (18), followed by mutation status (12) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO7B RNA expression–survival associations across cancer types. High MYO7B expression shows unfavorable associations in MESO and LUSC, but favorable associations in UVM, SCLC, KIRC and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MYO7B RNA expression.
This table summarizes MYO7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MYO7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO7B shows lower tumor expression in KICH, BLCA, LUAD and LUSC and higher tumor expression in HNSC and LIHC. The KICH box plot shows higher MYO7B RNA expression in normal versus tumor tissue (log2 FC = −2.712, t-test p < 0.001).
This table shows molecular features associated with MYO7B in patient tissues and cancer cell lines. In patient samples, MYO7B shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
